Krystal Biotech, Inc. (NASDAQ:KRYS) Shares Sold by Invesco Ltd.

Invesco Ltd. lowered its holdings in Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 24.7% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 275,195 shares of the company's stock after selling 90,356 shares during the quarter. Invesco Ltd. owned 0.96% of Krystal Biotech worth $43,112,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in KRYS. Norges Bank purchased a new stake in Krystal Biotech in the fourth quarter valued at $34,391,000. Raymond James Financial Inc. acquired a new position in shares of Krystal Biotech in the 4th quarter valued at about $15,989,000. Franklin Resources Inc. boosted its stake in shares of Krystal Biotech by 34.2% in the third quarter. Franklin Resources Inc. now owns 243,760 shares of the company's stock worth $43,774,000 after buying an additional 62,178 shares during the last quarter. TimesSquare Capital Management LLC grew its holdings in Krystal Biotech by 39.1% during the fourth quarter. TimesSquare Capital Management LLC now owns 158,868 shares of the company's stock worth $24,888,000 after acquiring an additional 44,646 shares during the period. Finally, Vanguard Group Inc. raised its position in Krystal Biotech by 1.0% during the fourth quarter. Vanguard Group Inc. now owns 2,878,451 shares of the company's stock valued at $450,938,000 after acquiring an additional 28,707 shares in the last quarter. Hedge funds and other institutional investors own 86.29% of the company's stock.

Analysts Set New Price Targets

Several equities research analysts have commented on the company. Citigroup upped their price objective on Krystal Biotech from $206.00 to $215.00 and gave the stock a "neutral" rating in a research report on Thursday, February 20th. Jefferies Financial Group started coverage on shares of Krystal Biotech in a report on Wednesday, March 5th. They set a "buy" rating and a $245.00 price target on the stock. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $215.00 price objective on shares of Krystal Biotech in a report on Thursday, February 20th. Chardan Capital increased their target price on shares of Krystal Biotech from $212.00 to $218.00 and gave the stock a "buy" rating in a research note on Thursday, February 20th. Finally, HC Wainwright restated a "buy" rating and issued a $221.00 price target on shares of Krystal Biotech in a research note on Friday, February 28th. One research analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Buy" and an average price target of $220.00.

Krystal Biotech Stock Up 4.3 %

Shares of Krystal Biotech stock traded up $6.89 during trading hours on Tuesday, reaching $168.80. 271,455 shares of the company's stock were exchanged, compared to its average volume of 295,790. The business has a fifty day moving average of $175.57 and a two-hundred day moving average of $171.70. The company has a market capitalization of $4.88 billion, a P/E ratio of 56.45 and a beta of 0.75. Krystal Biotech, Inc. has a 1 year low of $141.72 and a 1 year high of $219.34.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last released its quarterly earnings data on Monday, February 24th. The company reported $1.52 EPS for the quarter, beating analysts' consensus estimates of $1.29 by $0.23. The company had revenue of $91.10 million during the quarter, compared to the consensus estimate of $91.35 million. Krystal Biotech had a net margin of 30.69% and a return on equity of 11.41%. Krystal Biotech's quarterly revenue was up 116.4% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.30 EPS. As a group, research analysts predict that Krystal Biotech, Inc. will post 6.14 EPS for the current year.

Insider Activity at Krystal Biotech

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the firm's stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $177.79, for a total value of $4,444,750.00. Following the completion of the sale, the insider now directly owns 1,463,711 shares of the company's stock, valued at $260,233,178.69. This trade represents a 1.68 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CAO Kathryn Romano sold 750 shares of Krystal Biotech stock in a transaction on Thursday, February 27th. The stock was sold at an average price of $175.22, for a total value of $131,415.00. Following the transaction, the chief accounting officer now owns 12,604 shares in the company, valued at approximately $2,208,472.88. This represents a 5.62 % decrease in their position. The disclosure for this sale can be found here. Insiders own 13.70% of the company's stock.

Krystal Biotech Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).